

# Resource Summary Report

Generated by [ASWG](#) on Aug 4, 2026

## Certara

RRID:SCR\_021370

Type: Tool

---

### Proper Citation

Certara (RRID:SCR\_021370)

---

### Resource Information

**URL:** <https://www.certara.com/>

**Proper Citation:** Certara (RRID:SCR\_021370)

**Description:** Provides drug development software and services. Company offers drug development and clinical pharmacology strategy, regulatory strategy, writing and submission, as well as HEOR and market access solutions. Certara serves biopharmaceutical and medical technology customers worldwide.

**Synonyms:** , Certara USA, Inc., Certara

**Resource Type:** commercial organization

**Keywords:** Company, drug development software, drug development services, drug development strategy, clinical pharmacology strategy, regulatory strategy

**Resource Name:** Certara

**Resource ID:** SCR\_021370

**Record Creation Time:** 20220129T080355+0000

**Record Last Update:** 20260801T190708+0000

---

### Ratings and Alerts

No rating or validation information has been found for Certara.

No alerts have been found for Certara.

---

### Data and Source Information

**Source:** [SciCrunch Registry](#)

## Usage and Citation Metrics

We found 18 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [ASWG](#) .

Zhou XH, et al. (2025) A phase 1 study evaluating the safety, tolerability, and pharmacokinetics of the porcupine inhibitor, AZD5055. *iScience*, 28(6), 112602.

Basharat Z, et al. (2025) Proteome mining of *Yersinia Enterocolitica* for drug targets and computational inhibitor identification with ADMET, anti-inflammation potential and formulation characteristics. *BioData mining*, 18(1), 68.

Ishii K, et al. (2024) Crystal structure of Alzheimer's disease phospholipase D3 provides a molecular basis for understanding its normal and pathological functions. *The FEBS journal*, 291(24), 5398.

Wang J, et al. (2024) Phase 1a study of ESG401, a Trop2 antibody-drug conjugate, in patients with locally advanced/metastatic solid tumors. *Cell reports. Medicine*, 5(9), 101707.

Subbiah V, et al. (2023) Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(16), 2988.

Kagami L, et al. (2023) The ACPYPE web server for small-molecule MD topology generation. *Bioinformatics (Oxford, England)*, 39(6).

Ligon JA, et al. (2023) A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(2), 341.

Lammi C, et al. (2022) Mechanistic Insights into Angiotensin I-Converting Enzyme Inhibitory Tripeptides to Decipher the Chemical Basis of Their Activity. *Journal of agricultural and food chemistry*, 70(37), 11572.

Crudo F, et al. (2022) Persistence of the antagonistic effects of a natural mixture of *Alternaria* mycotoxins on the estrogen-like activity of human feces after anaerobic incubation. *Toxicology letters*, 358, 88.

Chen FW, et al. (2022) Activation of mitochondrial TRAP1 stimulates mitochondria-lysosome crosstalk and correction of lysosomal dysfunction. *iScience*, 25(9), 104941.

Fouqueray P, et al. (2021) Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: A phase 1b study. *Cell reports. Medicine*, 2(12), 100474.

Crudo F, et al. (2021) An in vitro study on the transport and phase II metabolism of the mycotoxin alternariol in combination with the structurally related gut microbial metabolite urolithin C. *Toxicology letters*, 340, 15.

Luo T, et al. (2021) Preclinical Pharmacokinetics, Tissue Distribution, and Primary Safety Evaluation of Indo5, a Novel Selective Inhibitor of c-Met and Trks. *Frontiers in pharmacology*, 12, 711126.

Croppi G, et al. (2020) Discovery of an Inhibitor for Bacterial 3-Mercaptopyruvate Sulfurtransferase that Synergistically Controls Bacterial Survival. *Cell chemical biology*, 27(12), 1483.

Ding F, et al. (2019) Probing the local conformational flexibility in receptor recognition: mechanistic insight from an atomic-scale investigation. *RSC advances*, 9(25), 13968.

Sernee MF, et al. (2019) A Family of Dual-Activity Glycosyltransferase-Phosphorylases Mediates Mannogen Turnover and Virulence in Leishmania Parasites. *Cell host & microbe*, 26(3), 385.

Togawa M, et al. (2016) Pharmacokinetics, Pharmacodynamics and Population Pharmacokinetic/Pharmacodynamic Modelling of Bilastine, a Second-Generation Antihistamine, in Healthy Japanese Subjects. *Clinical drug investigation*, 36(12), 1011.

Iitsuka H, et al. (2014) Pharmacokinetics of mirabegron, a  $\beta_3$ -adrenoceptor agonist for treatment of overactive bladder, in healthy Japanese male subjects: results from single- and multiple-dose studies. *Clinical drug investigation*, 34(1), 27.